Ramucirumab and Atezolizumab After Progression on Any Immune Checkpoint Blocker in NSCLC
Status:
Active, not recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
Data suggests that combining ramucirumab with immunotherapy in non-small cell lung cancer
(NSCLC) patients who have previously received immune checkpoint blockers (ICBs) may be more
effective than traditional therapy. The investigators propose a pilot study to test the
combination of ramucirumab and atezolizumab in patients with advanced-stage NSCLC patients
previously treated with ICB.